EUVIMEDEUVIMED entdecken
Crossref

Safety and Efficacy of Lutetium‐177 PSMA Radioligand Therapy in Metastatic Castration‐Resistant Prostate Cancer with Diffuse Bone Metastases (Asian Population Study)

Cherie Wei Qi Ng, Wei Ming Chua, Winnie Wing-Chuen Lam, Aaron Kian-Ti Tong, David Chee Eng Ng, Charlene Yu Lin Tang, Wei Ying Tham, Ravindran Kanesvaran, Alvin Seng Cheong Wong, Kae Jack Tay, Kenneth Chen, Sue Ping Thang

Asia-Pacific Journal of Clinical Oncology · 2025

DOI: 10.1111/ajco.14195 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Asia-Pacific Journal of Clinical Oncology, 2025. Verfasst von Cherie Wei Qi Ng und 11 weiteren Autor:innen. Beteiligte Einrichtung: Department of Diagnostic Imaging, National University Health System, Singapore, Singapore. Hauptthemen laut MEDLINE: Prostatic Neoplasms, Castration-Resistant, Lutetium, Bone Neoplasms, Radioisotopes. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 24 Literaturangaben.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Introduction

Prostate cancer is the second most common cancer and the leading cause of cancer‐related deaths in men. Patients with metastatic castration‐resistant prostate cancer (mCRPC) with diffuse bone metastases have limited treatment options due to severe hematological toxicity risks. This study evaluates the safety and efficacy of [ 177 Lu]Lu‐PSMA radioligand therapy (RLT) in this high‐risk group within an Asian population.

Methods

We conducted a retrospective analysis of 48 mCRPC patients with PSMA‐avid diffuse bone metastases treated with [ 177 Lu]Lu‐PSMA‐RLT between May 9, 2018 and Jan 10, 2023. Patients received up to 4 to 6 initial therapy cycles, with additional cycles considered for those who responded initially but later progressed. Primary and secondary endpoints included overall survival (OS), PSA progression‐free survival (PFS), PSA response, clinical response, and toxicity assessment.

Results

Median OS was 9.3 months. Any PSA response was observed in 75% of patients. Notably, 48% achieved a ≥50% PSA reduction, correlating with a longer median OS (11.6 vs. 8.6 months, p = 0.03). Median PSA PFS was 3.2 months, with improved outcomes observed in patients achieving ≥50% PSA reduction (6.0 vs. 1.8 months, p < 0.0001). Pain relief was reported in 43% of patients, with a median pain score reduction of 5 points. The most common adverse effect was hepatotoxicity, with anemia in 27%, neutropenia in 27%, and thrombocytopenia in 21%. Conclusion [ 177 Lu]Lu‐PSMA‐RLT demonstrates clinically meaningful benefits in survival and symptom management with an acceptable safety profile for mCRPC patients with extensive bone metastases. These findings support [ 177 Lu]Lu‐PSMA‐RLT as a viable treatment option for this challenging population.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Prostatic Neoplasms, Castration-ResistantLutetiumBone NeoplasmsRadioisotopesRadiopharmaceuticalsHumansMaleAgedRetrospective StudiesMiddle AgedAged, 80 and overGlutamate Carboxypeptidase II

Stichwörter der Autor:innen

diffuse bone metastaseslutetium‐177 PSMAmCRPCprostate cancerradioligand therapy

Substanzen

LutetiumLutetium-177RadioisotopesRadiopharmaceuticalsGlutamate Carboxypeptidase II

Autor:innen und Institutionen

  • Department of Diagnostic Imaging, National University Health System, Singapore, Singapore.
  • Department of Nuclear Medicine and Molecular Imaging, Singapore General Hospital, Singapore, Singapore.
  • Duke-NUS Medical School, Singapore, Singapore.
  • Department of Neuroradiology, Singapore General Hospital, Singapore, Singapore.
  • Division of Medical Oncology, National Cancer Centre Singapore, Singapore, Singapore.
  • Department of Haematology-Oncology, National University Cancer Institute, Singapore, Singapore, Singapore.

Zitieren

APA

Ng, C. W. Q., Chua, W. M., Lam, W. W., Tong, A. K., Ng, D. C. E., Tang, C. Y. L., Tham, W. Y., Kanesvaran, R., Wong, A. S. C., Tay, K. J., Chen, K., & Thang, S. P. (2025). Safety and Efficacy of Lutetium‐177 PSMA Radioligand Therapy in Metastatic Castration‐Resistant Prostate Cancer with Diffuse Bone Metastases (Asian Population Study). Asia-Pacific Journal of Clinical Oncology. https://doi.org/10.1111/ajco.14195

Vancouver

Ng CWQ, Chua WM, Lam WW, Tong AK, Ng DCE, Tang CYL, et al. Safety and Efficacy of Lutetium‐177 PSMA Radioligand Therapy in Metastatic Castration‐Resistant Prostate Cancer with Diffuse Bone Metastases (Asian Population Study). Asia-Pacific Journal of Clinical Oncology. 2025. doi:10.1111/ajco.14195

BibTeX
@article{Ng2025,
  author = {Ng, Cherie Wei Qi and Chua, Wei Ming and Lam, Winnie Wing-Chuen and Tong, Aaron Kian-Ti and Ng, David Chee Eng and Tang, Charlene Yu Lin and Tham, Wei Ying and Kanesvaran, Ravindran and Wong, Alvin Seng Cheong and Tay, Kae Jack and Chen, Kenneth and Thang, Sue Ping},
  title = {Safety and Efficacy of Lutetium‐177 PSMA Radioligand Therapy in Metastatic Castration‐Resistant Prostate Cancer with Diffuse Bone Metastases (Asian Population Study)},
  journal = {Asia-Pacific Journal of Clinical Oncology},
  year = {2025},
  doi = {10.1111/ajco.14195}
}
Kostenlos starten →